Factor VIII inhibitors.
The development of a Factor VIII inhibitor, an antibody that blocks its procoagulant function, is one of the most serious complications of hemophilia A treatment. Similar antibodies are also recognized as a rare cause of bleeding in previously healthy individuals who develop autoimmune anti-Factor VIII antibodies. Recent studies have yielded important information about these antibodies in four different areas: better understanding of the incidence of inhibitors following Factor VIII treatment; identification of patients at highest risk of inhibitor formation; characterization of anti-Factor VIII; and the development of better therapies.
Hoyer
L W
LW
American Red Cross, Rockville, Maryland, USA.
D000917:Antibody Formation; D001323:Autoantibodies / Q000097:blood; D005169:Factor VIII / Q000037:antagonists & inhibitors*; D020022:Genetic Predisposition to Disease; D006467:Hemophilia A / Q000276:immunology / Q000628:therapy*; D006801:Humans
D001323:Autoantibodies; D005169:Factor VIII